Results 201 to 210 of about 45,611 (300)

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu   +4 more
wiley   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang   +8 more
wiley   +1 more source

One‐Step Glycoengineering of NK Cells With High‐Affinity Siglec Ligands for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
This study develops an engineered NmCSS enzyme with improved activity for bulky group modified sialic acids, enabling efficient synthesis of structurally diverse sialoside analogs in a single step. Glycan microarray screening identified Siglec high‐affinity ligands, which were incorporated onto natural killer (NK) cells via a one‐pot enzymatic system ...
Shuai Hu   +8 more
wiley   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

open access: yesAdvanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang   +6 more
wiley   +1 more source

Detachment‐Induced FAK‐STAT3‐NNMT Inhibits CTCs Anoikis to Promote Breast Cancer Metastasis by Enhancing Fatty Acid Oxidation

open access: yesAdvanced Science, EarlyView.
The FAK‐STAT3‐NNMT axis drives anoikis resistance in circulating tumor cells by reprogramming fatty acid oxidation. Targeting this metabolic vulnerability suppresses metastasis, untangling a key mechanism of breast cancer progression and revealing NNMT as a promising therapeutic target.
Qingchao Tong   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy